Similar articles

• First-line pembrolizumab plus lenvatinib is effective in non-clear-cell RCC.

  Romero D. Romero D. Nat Rev Clin Oncol. 2023 Oct;20(10):661. doi: 10.1038/s41571-023-00809-3. Nat Rev Clin Oncol. 2023. PMID: 37507496 No abstract available.
• Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.

  Lee CH, Shah AY, Rasco D, Rao A, Taylor MH, Di Simone C, Hsieh JJ, Pinto A, Shaffer DR, Girones Sarrio R, Cohn AL, Vogelzang NJ, Bilen MA, Gunnestad Ribe S, Goksel M, Tennøe ØK, Richards D, Sweis RF, Courtright J, Heinrich D, Jain S, Wu J, Schmidt EV, Perini RF, Kubiak P, Okpara CE, Smith AD, Motzer RJ. Lee CH, et al. Lancet Oncol. 2021 Jul;22(7):946-958. doi: 10.1016/S1470-2045(21)00241-2. Epub 2021 Jun 15. Lancet Oncol. 2021. PMID: 34143969 Free PMC article. Clinical Trial.
• Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale.

  Grünwald V, Powles T, Choueiri TK, Hutson TE, Porta C, Eto M, Sternberg CN, Rha SY, He CS, Dutcus CE, Smith A, Dutta L, Mody K, Motzer RJ. Grünwald V, et al. Future Oncol. 2019 Mar;15(9):929-941. doi: 10.2217/fon-2018-0745. Epub 2019 Jan 28. Future Oncol. 2019. PMID: 30689402
• The Efficacy of Lenvatinib and Everolimus in Chromophobe-type Non-Clear-Cell Renal Cell Carcinoma: A Case Report and Literature Review.

  Schwartz C, Pfanzelter N, Kuzel TM. Schwartz C, et al. Clin Genitourin Cancer. 2017 Oct;15(5):e903-e906. doi: 10.1016/j.clgc.2017.05.017. Epub 2017 May 25. Clin Genitourin Cancer. 2017. PMID: 28624319 Review. No abstract available.
• The implementation of lenvatinib/everolimus or lenvatinib/pembrolizumab combinations in the treatment of metastatic renal cell carcinoma.

  Jacob A, Shook J, Hutson T. Jacob A, et al. Expert Rev Anticancer Ther. 2021 Apr;21(4):365-372. doi: 10.1080/14737140.2021.1868994. Epub 2021 Jan 6. Expert Rev Anticancer Ther. 2021. PMID: 33393393 Review.